Reaction
Rheumatic Disorder reporting signals
As of the last recalculation, Rheumatic Disorder appears in 1,918 FAERS reports alongside 32 co-occurring drug terms. The strongest observed disproportionality signal is ICOSAPENT ETHYL (PRR 54.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Icosapent Ethyl | 42 | 54.7 | 55.0 |
| Calcium Gluconate | 30 | 27.4 | 27.5 |
| Desoximetasone | 43 | 25.0 | 25.1 |
| Rosuvastatin Calcium | 45 | 17.7 | 17.8 |
| Sulfasalazine | 114 | 16.7 | 16.8 |
| Moxifloxacin Hydrochloride | 30 | 16.3 | 16.3 |
| Leflunomide | 115 | 12.6 | 12.6 |
| Olmesartan Medoxomil | 37 | 11.4 | 11.4 |
| Hydroxychloroquine Sulfate | 90 | 11.2 | 11.2 |
| Durvalumab | 20 | 10.8 | 10.8 |
| Adalimumab-Fkjp | 43 | 10.3 | 10.3 |
| Golimumab | 78 | 10.2 | 10.3 |
| Adalimumab-Adaz | 48 | 10.1 | 10.1 |
| Adalimumab-Aaty | 42 | 9.8 | 9.8 |
| Certolizumab Pegol | 93 | 9.0 | 9.0 |
| Upadacitinib | 65 | 8.9 | 8.9 |
| Abatacept | 108 | 8.9 | 8.9 |
| Hydroxychloroquine | 59 | 8.8 | 8.8 |
| Nivolumab | 73 | 8.5 | 8.5 |
| Tocilizumab | 84 | 8.3 | 8.3 |
| Ipilimumab | 29 | 7.4 | 7.4 |
| Valsartan And Hydrochlorothiazide | 9 | 7.2 | 7.2 |
| Adalimumab | 388 | 7.2 | 7.2 |
| Secukinumab | 89 | 6.2 | 6.2 |
| Atezolizumab | 21 | 5.9 | 5.9 |
| Entecavir | 6 | 5.6 | 5.6 |
| Glecaprevir And Pibrentasvir | 5 | 4.9 | 5.0 |
| Pembrolizumab | 45 | 4.7 | 4.7 |
| Etanercept | 232 | 4.6 | 4.6 |
| Tofacitinib | 67 | 4.0 | 4.0 |
| Fremanezumab-Vfrm | 4 | 3.8 | 3.8 |
| Ustekinumab | 33 | 3.5 | 3.5 |